Aortic stenosis and hyperlipidemia: Establishing a cause-effect relationship

American Heart Journal

Volumn 147, Issue 5, 2004, Pages 761-763

  Otto, Catherine M ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METALLOPROTEINASE; OSTEOPONTIN;

AORTA STENOSIS; AORTA VALVE; AORTA VALVE DISEASE; ATHEROSCLEROSIS; CALCIFICATION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; EDITORIAL; FIBROBLAST; HEMODYNAMICS; HISTOLOGY; HUMAN; HYPERLIPIDEMIA; IMMUNITY; INFLAMMATORY CELL; LIPID STORAGE; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR;

ANALYSIS OF VARIANCE; AORTIC VALVE STENOSIS; CALCINOSIS; DISEASE PROGRESSION; HUMANS; HYPERLIPIDEMIAS;

EID: 3042851664     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2003.12.014     Document Type: Editorial

References (21)

1. Otto C.M., Kuusisto J., Reichenbach D.D., et al. Characterization of the early lesion of 'degenerative' valvular aortic stenosis histologic and immunohistochemical studies. Circulation. 90:1994;844-853
2. Olsson M., Dalsgaard C.J., Haegerstrand A., et al. Accumulation of T lymphocytes and expression of interleukin-2 receptors in nonrheumatic stenotic aortic valves. J Am Coll Cardiol. 23:1994;1162-1170
3. O'Brien K.D., Reichenbach D.D., Marcovina S.M., et al. Apolipoproteins B, (a) and E accumulate in the morphologically early lesion of "degenerative" valvular aortic stenosis. Arterio and Thrombosis. 16:1996;523-532
4. Olsson M., Thyberg J., Nilsson J. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler Thromb Vasc Biol. 19:1999;1218-1222
5. Mohler E.R.I., Adam L.P., McClelland P., et al. Detection of osteopontin in calcified human aortic valves. Arterioscler Thromb Vasc Biol. 17:1997;547-552
6. O'Brien K.D., Kuusisto J., Reichenbach D.D., et al. Osteopontin is expressed in human aortic valvular lesions. Circulation. 92:1995;2163-2168
7. O'Brien K.D., Shavelle D.M., Caulfield M.T., et al. Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation. 106:2002;2224-2230
8. Mohler E.R. III, Gannon F., Reynolds C., et al. Bone formation and inflammation in cardiac valves. Circulation. 103:2001;1522-1528
9. Stewart B.F., Siscovick D., Lind B.K., et al. Clinical factors associated with calcific aortic valve disease. J Am Coll Cardiol. 29:1997;630-634
10. Otto C.M., Burwash I.G., Legget M.E., et al. A prospective study of asymptomatic valvular aortic stenosis clinical, echocardiographic, and exercise predictors of outcome. Circulation. 95:1997;2262-2270
11. Rosenhek R, Klaar U, Scholten C, et al. Mild and moderate aortic stenosis: natural history and risk stratification by echocardiography. Eur Heart J 2004;25:199-205
12. Ngo M.V., Gottdiener J.S., Fletcher R.D., et al. Smoking and obesity are associated with the progression of aortic stenosis. Am J Geriatr Cardiol. 10:2001;86-90
13. Palta S., Pai A.M., Gill K.S., et al. New insights into the progression of aortic stenosis implications for secondary prevention. Circulation. 101:2000;2497-2502
14. Yilmaz M.B., Guray U., Guray Y., et al. Lipid profile of patients with aortic stenosis might be predictive of rate of progression. Am Heart J. 147:2004;915-918
15. Rajamannan N.M., Subramaniam M., Springett M., et al. Atorvastatin inhibits hypercholesterolemia-inducedcellular proliferation and bone matrix production in the rabbit aorticvalve. Circulation. 105:2002;2660-2665
16. Drolet M.C., Arsenault M., Couet J. Experimental aortic valve stenosis in rabbits. J Am Coll Cardiol. 41:2003;1211-1217
17. Aronow W.S., Ahn C., Kronzon I., et al. Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol. 88:2001;693-695
18. Novaro G.M., Tiong I.Y., Pearce G.L., et al. Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis. Circulation. 104:2001;2205-2209
19. Shavelle D.M., Takasu J., Budoff M.J., et al. HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet. 359:2002;1125-1126
20. Bellamy M.F., Pellikka P.A., Klarich K.W., et al. Association of cholesterol levels, hydroxymethylglutaryl coenzyme-a reductase inhibitor treatment, and progression of aortic stenosis in the community. J Am Coll Cardiol. 40:2002;1723-1730
21. Pohle K., Maffert R., Ropers D., et al. Progression of aortic valve calcification association with coronary atherosclerosis and cardiovascular risk factors. Circulation. 104:2001;1927-1932